Calithera Biosciences Inc. (CALA) Trading Down 3.1%
Calithera Biosciences Inc. (NASDAQ:CALA)’s share price traded down 3.1% during mid-day trading on Thursday . The company traded as low as $3.61 and last traded at $3.69, with a volume of 184,954 shares. The stock had previously closed at $3.81.
A number of equities analysts have recently issued reports on the stock. Wells Fargo & Co. reiterated a “buy” rating on shares of Calithera Biosciences in a research report on Thursday, May 12th. Zacks Investment Research lowered shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, May 17th. Finally, JMP Securities reiterated a “buy” rating on shares of Calithera Biosciences in a research report on Wednesday, June 8th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $10.48.
The firm’s market cap is $68.81 million. The firm’s 50-day moving average is $4.56 and its 200 day moving average is $5.41.
Calithera Biosciences (NASDAQ:CALA) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.47) by $0.05. Equities research analysts predict that Calithera Biosciences Inc. will post ($2.15) EPS for the current fiscal year.
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.